Format

Send to

Choose Destination
See comment in PubMed Commons below
Version 3. PLoS Curr. 2012 Feb 15 [revised 2012 Mar 26];4:RRN1304.

Current Pharmacological Management in Juvenile Huntington's Disease.

Author information

  • 1Department of Clinical Genetics, Sheffield Children's Hospital, Sheffield UK S10 2TH; Neurogenetics and Rare Diseases Centre, IRCCS Neuromed, Pozzilli (IS), Italy.; University of Cambridge; Department of Clinical Neurophysiology, Institute of Psychiatry and Naurology, Warsaw, Poland and Dept. of Neurology, University of Ulm, Ulm, Germany.

Abstract

BACKGROUND:

The clinical presentation of Juvenile Huntington's Disease (JHD) can be very different from adult-onset HD with little evidence to guide symptomatic management.

AIM:

To survey the current use of pharmacological treatments for JHD.

METHODS:

Patients were identified through the HD Association, Hospital Doctors and the European Huntington's Disease Network REGISTRY study.

RESULTS:

The most commonly prescribed agents were anti-psychotics (24/45), anti-depressants (17/45) and anti-parkinsonian medications (15/45). 5 patients were taking more than 8 medications.

CONCLUSIONS:

The most commonly prescribed group of medication was the anti-psychotic. Many patients were on multiple therapies, highlighting the need to rationalise medications.

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Public Library of Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk